China Biologic Products Holdings, Inc.
CBPO
CBPO was delisted on the 20th of April, 2021.
69 hedge funds and large institutions have $1.3B invested in China Biologic Products Holdings, Inc. in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 27 reducing their positions, and 8 closing their positions.
128% more call options, than puts
Call options by funds: $22.5M | Put options by funds: $9.87M
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
17% more capital invested
Capital invested by funds: $1.11B → $1.3B (+$191M)
3% more funds holding
Funds holding: 67 → 69 (+2)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
30% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Greenwoods Asset Management
Grand Cayman,
Cayman Islands
|
+$29M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$18.2M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$8.12M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$5.4M |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
+$4.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$26M |
| 2 |
YCMGA
York Capital Management Global Advisors
New York
|
-$17.7M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
-$15.2M |
| 4 |
KLCMU
Kite Lake Capital Management (UK)
London,
United Kingdom
|
-$14.8M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$14.5M |
CBPO Hedge Fund Activity: Q1 2019 in Review
69 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q1 2019, worth a combined $1.3B — up 17% from $1.11B a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new CBPO positions and 8 closed out — a net gain of 3 holders — while 19 added to existing stakes and 27 trimmed.
The largest buyer was Greenwoods Asset Management, adding an estimated $29M. The largest seller was Fidelity Investments, cutting an estimated $26M.
- 69 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q1 2019, up from 67 in Q4 2018.
- Funds reported $1.3B of China Biologic Products Holdings, Inc. stock for Q1 2019, up 17% quarter-over-quarter.
- 11 funds opened new China Biologic Products Holdings, Inc. positions in Q1 2019 and 8 closed out, a net change of +3 holders.
- The largest China Biologic Products Holdings, Inc. buyer in Q1 2019 was Greenwoods Asset Management, an estimated $29M added.
- The largest China Biologic Products Holdings, Inc. seller in Q1 2019 was Fidelity Investments, an estimated $26M sold.
Based on aggregated 13F filings for Q1 2019.